Table 1.
Demographic and clinical characteristics
| Characteristics | Patients no (%) | ||
|---|---|---|---|
| Non‐COPD (n = 93) | COPD (n = 107) | P | |
| Mean age ± SD | 74.3 ± 9.6 | 78.6 ± 9.05 | 0.001 |
| Range | 50 ~ 91 | 54 ~ 101 | |
| Age ≥75 y olda | |||
| Yes | 47 (50.5) | 79 (73.8) | 0.001 |
| No | 46 (49.5) | 28 (26.2) | |
| Gendera | |||
| Male | 86 (92.5) | 103 (96.3) | 0.241 |
| Female | 7 (7.5) | 4 (3.7) | |
| Smoking index, Pack‐yearsa | |||
| ≥20 | 36 (38.7) | 63 (58.9%) | 0.004 |
| <20 | 57 (61.3%) | 44 (41.1%) | |
| Pulmonary function test | |||
| FEV1/FVC, % | 77.6 ± 5.8 | 59.75 ± 8.3 | <0.001 |
| Predicted FEV1, % | 99.17 ± 19.1 | 72.12 ± 21.0 | <0.001 |
| FEV1, L | 2.3 ± 0.6 | 1.6 ± 0.6 | <0.001 |
| FVC, L | 3.0 ± 0.7 | 2.7 ± 0.8 | 0.002 |
| FVC, % | 92.6 ± 19.0 | 83.9 ± 20.8 | 0.003 |
| COPD severity | |||
| Mild | 48 (44.9) | ||
| Moderate | 39 (36.4) | ||
| (Very) Severe | 20 (18.7) | ||
| ECOG PS scorea | |||
| 0 ~ 1 | 57 (61.3) | 45 (42.1) | 0.007 |
| ≥2 | 36 (38.7) | 62 (57.9) | |
| TNM stagea | |||
| Ⅰ | 63 (67.7) | 57 (53.3) | 0.026 |
| Ⅱ | 6 (6.5) | 3 (2.8) | |
| Ⅲ | 11 (11.8) | 29 (27.1) | |
| Ⅳ | 13 (14.0) | 18 (16.8) | |
| Histologic subtypea | |||
| Squamous cell carcinoma | 19 (20.4) | 31 (29.0) | 0.344 |
| Adenocarcinoma | 54 (58.1) | 49 (45.8) | |
| Adenosquamous carcinoma | 1 (1.1) | 4 (3.7) | |
| NSCLC, NOS | 15 (16.1) | 17 (15.9) | |
| Others | 4 (4.3) | 6 (5.6) | |
| Initial treatmenta | |||
| Surgery | 45 (48.4) | 31 (29.0) | 0.031 |
| Radiation | 17 (18.3) | 32 (29.9) | |
| Chemotherapy | 9 (9.7) | 11 (10.3) | |
| Target therapy | 15 (16.1) | 16 (15.0) | |
| BSC | 7 (7.5) | 17 (15.9) | |
| Previous tumorsa | |||
| Yes | 24 (25.8) | 34 (31.8) | 0.353 |
| No | 69 (74.2) | 73 (68.2) | |
| Serum level of CEA, ng/mL | 21.4 ± 139.8 | 34.5 ± 300.2 | 0.7 |
| Serum level of D2‐dimer | 1.0 ± 1.7 | 0.9 ± 1.5 | 0.751 |
| Neutrophil‐lymphocyte ratio | 1.8 ± 1.0 | 3.5 ± 2.0 | <0.001 |
Abbreviations: BSC, best supportive care; CEA, carcinoembryonic antigen; COPD, chronic obstructive pulmonary disease; ECOG PS, Eastern Cooperative Oncology Group performance status; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; NLR, neutrophil‐lymphocyte ratio.
a
Variable were used to compute propensity scores.